Weekly Highlights: Guangzhou Pharma Chairman Under Investigation; DRG/DIP 2.0 Grouping Scheme Released
Johnson & Johnson
Medical Device R&D and Manufacturer
Gan&Lee Pharmaceuticals
Biological Synthetic Human Insulin Pharmaceutical R&D Manufacturer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Sanofi
Pharmaceutical Manufacturer
"Weekly Highlights"
"Weekly Highlights" is a column launched by Siqi Club to summarize the major events in the pharmaceutical industry each week, covering the latest policy updates, news, pharmaceutical finance, drug approval progress and other industry-related content.
Personnel Changes
HUMAN RESOURCES
General Manager of Pfizer's Division Resigns
Pfizer Announces Departure of Song Faxian, General Manager of China Hematology and Rare Disease Business Unit. His last working day at Pfizer will be July 26, 2024.
Chairman of Guangzhou Pharmaceutical Investigated
On the evening of July 22, Baiyun Mountain, a listed company under Guangzhou Pharmaceutical Holdings Limited (Guangyao Group), disclosed that Li Chuyuan had resigned from his positions as chairman of the company and would no longer hold any position in the company. Reporters from the First Financial News confirmed through multiple independent sources that Li Chuyuan has been taken away by relevant authorities for investigation.
Policy Brief
POLICY
National Healthcare Security Administration: Release of DRG/DIP 2.0 Version Grouping Plan
On July 23, the National Healthcare Security Administration held a press conference in Beijing to announce the DRG/DIP 2.0 version grouping plan, officially releasing the new version of the DRG/DIP grouping plan.
Pharmaceutical News Updates
PHARMA
Johnson & Johnson Intracardiac Ultrasound Catheter Approved for Marketing
On July 23, according to the NMPA website, Johnson & Johnson's intracardiac ultrasound catheter was approved for marketing.
Samsung Bioepis' Eculizumab Biosimilar Receives FDA Approval
On July 22, Samsung Bioepis announced that the U.S. FDA had approved its biosimilar Eculizumab, Epysqli, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Gan&Lee Pharmaceuticals Announces Latest Results of Weight Loss Drug
On July 22, Gan&Lee Pharmaceuticals announced the Phase 2b clinical data of its long-acting GLP-1 receptor agonist biweekly formulation GZR18. After 30 weeks of treatment, patients in the 12mg, 18mg, 24mg, and 48mg dose groups experienced weight loss of 11.15%, 13.22%, 14.25%, and 17.29%, respectively.
Pharmaceutical Finance
BUSINESS
AstraZeneca's Total Revenue in the First Half of the Year: $25.617 Billion
On July 25, AstraZeneca announced its financial report for the first half of the year. During the reporting period, the company's total revenue was $25.617 billion, including $24.629 billion in product revenue, representing an 18% year-over-year increase. Focusing on specific products, dapagliflozin generated nearly $4 billion, osimertinib revenue reached $3.2 billion, and DS8201 reported $932 million in revenue for the first half of the year.
Roche's Total Revenue in the First Half of the Year: CHF 29.848 Billion
On July 25, Roche announced its financial report for the first half of the year. During the reporting period, the company's total revenue was 29.848 billion Swiss francs, approximately 33.719 billion US dollars, representing a year-on-year increase of 5%; net profit was 6.697 billion Swiss francs, approximately 7.566 billion US dollars, representing a year-on-year decrease of 4%.
Sanofi's Total Revenue in the First Half of the Year: €21.209 Billion
On July 25, Sanofi announced its financial report for the first half of the year. During the reporting period, the company's total revenue was 21.209 billion euros, an increase of 8.4% year-on-year. Of this, pharmaceutical business revenue was 16.059 billion euros, an increase of 9.6% year-on-year, vaccine revenue was 2.319 billion euros, and consumer health business revenue was 2.831 billion euros.
Business Cooperation
130 6172 3098
zakk.cui@siqibest.com
ClickRead the Original Text Learn More